HighTower Advisors LLC Sells 32,629 Shares of Pfizer Inc. $PFE

HighTower Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,615,514 shares of the biopharmaceutical company’s stock after selling 32,629 shares during the period. HighTower Advisors LLC’s holdings in Pfizer were worth $62,982,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Keb Asset Management LLC purchased a new stake in Pfizer in the second quarter worth $26,000. Field & Main Bank bought a new stake in Pfizer in the second quarter valued at $27,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. increased its position in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Stock Performance

Shares of Pfizer stock opened at $28.42 on Tuesday. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21. The firm has a market capitalization of $161.98 billion, a P/E ratio of 37.40, a P/E/G ratio of 1.91 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $26.06 and a two-hundred day simple moving average of $26.34.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.